Introduction
The sulfonyl carbamate functional group is an easily accessible carboxylic acid bioisostere, and is traditionally introduced in the N-acylation of sulfonamides with carbonic acid derivatives such as chloroformate or anhydride. [1] Sulfonyl carbamates are also used as nitrogen nucleophilesint he Mitsonobu reaction, [2] as protecting groups for alcohols [3] and as dehydrating reagents. [4] The sulfonyl carbamate moiety can be found in molecules with anticancer, [5] herbicidal, [6] lipid-regulating, [7] and antibacterial [8] properties. Furthermore, it is present in ap lethora of ligands [9] to the angiotensin II subtype1 and 2r eceptors (AT 1 Ra nd AT 2 R, respectively), as ubjecto fo ngoing research interest in our laboratory. [10] Compound 21 (C21, see Scheme 1), the first non-peptide AT 2 Rs elective agonist, [11] is currently in clinicalt rials for the treatment of idiopathic pulmonary fibrosis and hasb een the subject of intense study since its disclosure. [12] In addition to its beneficial effects in animal models of cardiovascular disorders, [13] stroke, [14] and spinal cord injury, [15] C21 represents ap ossible therapeutic alternative in the managemento fp rostate cancer, the leadingc ause of cancer in Europeanm en. [16, 17] As AT 2 Re xpression has been shown to decrease with disease progression, we envisioned that the use of ar adio-labeled selectiven on-peptideA T 2 Ra gonist would provide ap otential means for the monitoring and staging of prosScheme1.Representative sulfonyl carbamates,including C21-the first nonpeptideangiotensin II receptors ubtype 2agonist.
We describet he development of an ew methodology focusing on 11 C-labeling of sulfonyl carbamates in am ulticomponent reaction comprised of as ulfonyla zide, an alkyl alcohol, and [ 11 C]CO. An umber of 11 C-labeled sulfonyl carbamates were synthesized and isolated, and the developedm ethodology was then appliedi nt he preparation of ab iologically active molecule. The target compound was obtained in 24 AE 10 %i solated radiochemical yield and was evaluated for binding properties in at umor cell assay; in vivo biodistribution and imagings tudies were also performed. This represents the first successful radiolabeling of an on-peptide angiotensin II receptor subtype 2 agonist, C21, currentlyinclinical trials for the treatment of idiopathic pulmonary fibrosis.
tate cancer,a sw ell of investigatingA T 2 Rf unction and the in vivo properties of non-labeled C21.
The use of positron emission tomography (PET) allows noninvasive visualization of biological processes at the molecular or cellular level. [18, 19] This is achieved by the incorporation of as hort-lived radionuclide such as 11 C (t 1/2 = 20.4 min) into an organicm olecule, which can then be administered as at racer. To this end, severalc lasses of non-peptideA T 2 Rl igandsh ave previously been reported by Hallberg and co-workers [11, [20] [21] [22] and a 11 C-labeled benzamide ligand was evaluated for tracer properties andb iodistribution. [23] Although the ligand tested did not displayf avorable metabolic properties, we wished to extend this work to include C21, the most potent and wellstudied ligand to this receptor.T ot he best of our knowledge, there is no existing methodology for the preparation of 11 C-labeled sulfonyl carbamates. We, therefore, turned our efforts to the development of ag eneral methodology that would enable synthesis, purification,a nd formulation of 11 C-sulfonyl carbamates within the time constraints induced by our radionuclide of choice. This methodology could then be appliedt ot he preparation of
Having identified as uitable target compound, we envisioned am ulticomponent [24] approacht ot he synthesis of [ in the direct synthesis of carbamates from amines and alkyl halides, [25] to the best of our knowledge,t his methodology has not been tested with sulfonamides as the nucleophilic component (route A). Rh I -mediated carbonylation chemistry,o nt he other hand, is well-suited to radionuclide incorporation by using sulfonyl azides and [
11 C]CO (route B). [26] We, therefore, chose to expand the scope of carbonylation chemistry,e mploying as ulfonyl azide and an alcohol as the nucleophilic component. Relying on recently disclosed methodology that enablesc onfinemento f[
11 C]CO in small-volumer eaction vessels at low pressure by using soluble xenon as the transfer gas, [27] we sought to develop as ynthetic route to 11 C-labeled sulfonyl carbamates. The potential of multicomponent reactions in terms of robustness and operational simplicity would then be harnessed to afford rapid access to structurally diverse 11 C-carbamates. Herein, we describe the development of an ovel methodo fp reparing 11 C-sufonyl carbamates and its application in the synthesis of [ 11 C]C21.
Results and Discussion

Model Carbamates
By using chemistry developed in our group, [28, 29] an umber of sulfonyl azide precursors were prepared and converted to the corresponding isotopically unmodified sulfonyl carbamates, which were then used as analytical standards. With previous work on aryl azides [30] and sulfonyl azides [26] as entry points, we carried out ap reliminary screening of reaction conditions (Table 1) for the synthesis of 11 C-sulfonyl carbamates, using thiophene-2-sulfonyl azide (1a)a samodel substrate. Inspired by the efforts of Long and Ning, [31] we began our catalyst screen with PdCl 2 ,areadily available and inexpensive catalyst. However,i tq uicklyb ecamea pparent that PdCl 2 was not amenable to the scale on which 11 C-labelingr eactions are normally conducted. The poor solubility of PdCl 2 in selected solvents (DMA, DMF and THF) hindered the preparation of stock solutions, and it was observed to catalyze the formation of multiple 11 C-labeled side products ( [32] led us to select Pd(PPh 3 ) 4 ,acommon choice for transition-metal-mediated 11 C-carbonylationr eactions. [23, 33, 34] We were pleased to see ar elativelyl arge increasei nc onversion and NIRCY (entry 3), but increasing the temperature had ad etrimental effect on both conversion and NIRCY (entries 4a nd 5). Pd(OAc) 2 has been used [35] in the synthesis of sulfonylureas from the corresponding sulfonyl chlorides andC O, but ac onversion of 48 %a nd an on-isolated radiochemical yield of 43 % prompted us to investigate Rh I as ac atalyst. Earlier work [26] in our group demonstrated the utility of Rh I in aminocarbonylation reactions of sulfonyl azides, and [Rh(COD)Cl] 2 and PPh 3 at 75 8Cg ave ac onversion of 95 %a nd an NIRCY of 86 % (entry 7). Increasing the temperature to 100 8Cg ave similarr esults, but increasing to 120 8Ch ad an egative impacto nb oth conversion and NIRCY (entries 8a nd 9). Increasing the concentrationo fP Ph 3 to achieve aP /Rh ratio of 3:1i no rder to form the Wilkinson's catalyst [36] gave ac omparable conversion and an NIRCY of 88 %( entry 10), leadingu st os elect these conditions. Moreover,w ew ere pleased by the superior performance of the ubiquitous PPh 3 compared to bidentate ligands of varying bite angles (Xantphos, dppf, and dppp;entries [11] [12] [13] .
Having demonstrated the viability of this strategy,w et hen appliedi tt ot he synthesis of av ariety of functionalized 11 C-labeled sulfonyl carbamates (Table2). We began by investigating the scope of the alcoholc omponent, using p-toluene sulfonyl azide (tosyl azide, Ts N 3 , 1b)a sthe azide scaffold. Gratifyingly, n-butanol performed well with Ts N 3 ,forming 11 C-sulfonyl carbamate 2b in as lightly lower isolated yield as compared to thiophene-2-sulfonyl azide. Secondary alcohols gave comparable yields (2c and 2d), but the use of benzyl alcohol resulted in al ower isolated radiochemicaly ield, despite good conversion of gaseous [ 11 C]CO (2e). 2-Thiophenemethanol gave an isolated radiochemical yield of 23 %( 2f), whereas hindered alcohols gave low,a lbeit isolable yields (2g, 2h), and in the case of 2g, an umber of unidentified labeled side products were observed.
Havinge xplored the scope of alcohols that could be used in this reaction, we then investigated an umber of sulfonyl azides (Table 3) . We were pleased to observe the compatibility of structurally diverses ulfonyla zides with our reaction system. Electron-rich and electron-poor arylsulfonyl azides gave comparable isolatedr adiochemical yields (3a and 3b)w ith slightly lower conversion of gaseous [ 11 C]CO as comparedt oT sN 3 .N otably,t he use of as ulfonyl azide on an sp 3 carbon gave good conversion and an isolated radiochemical yield of 51 %( 3c). This observation is in agreement with our results when using isotopically unmodified CO and PdCl 2 .
[28] The use of aheteroaryl sulfonyl azide gave ar educed, albeit isolable yield (3d), and in the case of 3e,w ew ere pleased to see ac onversion of 85 % and an on-isolated radiochemical yield of 71 %.
Inspired by the work of Collinsa nd Glorius, [37] we then tested the susceptibility of our reaction manifold to several potential contaminants and other detrimental factors (Table3). To our surprise, the presence of both af ree carboxylic acid and ab asic nitrogen centert hat could potentially interfere with metal catalysts was tolerated (albeit with the formationo fs everal 11 C-labeled side products;T able 3, entry 1). Similarly,anonisolated radiochemical yield of 50 %w as observed when using phenylacetylene as an additive (entry 2). This indicated that the sulfonyl azide starting material was available forr eaction, despite its ability to undergo azide-alkyne cycloaddition. [38] Conversely,t he addition of excessH 2 Op rovedt ob ed etrimental, as did the omissiono fc atalyst( entries 3a nd 4). Finally,t he use of 24 ho ld stock solutionse xposed to light resultedi n an on-isolated radiochemicaly ield of 6%,m ost probably owing to catalyst decomposition (entry 5). 
Synthesis of Key Sulfonyl Azide Precursor
Following route B, the key sulfonyl azide precursor 1n was prepared in five steps, startingf rom the commercially available tert-butyl sulfonamide 1h (Scheme 3). Treatmento f1h with excess nBuLi followed by 1-bromo-2-methylpropane afforded the 5-alkylated product 1I,a nd subsequent lithiation and borylation led to boronic acid 1i.T his was then subjected to aS uzuki-Miyaura [39] cross-coupling reaction with imidazole derivative 1j,s ynthesized from 4-bromobenzyl bromide, to give 1l.A fter deprotection with neat TFA, the primary sulfonamide 1m was converted into key sulfonyl azide precursor 1n throughadiazotransfer from an imidazole-1-sulfonyl azide salt, demonstrating the utility of this methodology for late-stage azidation. [29, 40] 
Preparation of [ 11 C]C21
With precursor 1n in hand, we then turned our attentiont o the preparation of [ 11 C]C21 (see Scheme 4). Following our newly-developed protocol, [ 11 C]C21 was isolated in 24 AE 10 % radiochemical yield (decay-corrected, n = 9) andt he specific activity after [ 11 C]CO introductionw as 34-51 GBq mmol À1 (n = 3). Gratifyingly,t he synthesis of [ 11 C]C21 was robust and multiple batches could be prepared for biological evaluation and imaging purposes.
In Vitro Binding Specificity
The DU145 cell line (a brain metastasis of human prostatec arcinoma [41] )w as chosen fore valuation of the in vitro binding characteristics of [ 11 C]C21. Measured activity was significantly lower in samples that were pre-incubated with non-labeled C21, indicating specificb inding (see Figure 1) . As demonstrated by Guimonde tal., [16] the presence of AT 2 Ri nn on-tumoral prostatet issue and early-stage prostate tumors suggests limited proliferation.Aradiolabeledi maging agent could,therefore, be used to stage disease progression and aid in the provision of individualized therapy.
Biodistribution
Havingd emonstrated the in vitro utility of [ intestine with contentst hat, in conjunction with rapid clearance from blood, indicatef ast eliminationk inetics. Very low levels of activity were detected in all other organs. Although the AT 2 Rh as been previously detected in the pancreas and sexual organs, [42] only low activity was detected in these organs.
MicroPET-CT
The fused PET/CT images over the abdomen showed the same distribution pattern for the anaesthetized male rats (Figure 3) as that determined by ex vivo biodistribution studies when using un-sedated femaler ats. The only organ that was clearly distinguishable wast he liver.H owever,b yu sing earlyf rames, regions of interest( ROIs) could be drawn also for the aorta and the left kidney,a nd time activity curves were generated. The kinetics of [ 
Conclusions
Ag eneral methodology for the 11 C-labeling of sulfonyl carbamates in aR h I -mediated multicomponent reaction has been developed and demonstrated by the preparationo f1 2 11 C-sulfonyl carbamates. The radiolabeling of ap otent,n on-peptide AT 2 Ra gonist (C21) wast hen successfully performed and the isolated compound was found to bind specificallyi np rostate tumor cells expressing AT 2 R. The biological evaluation of [ 11 C]C21 indicates rapid metabolism and excretion,t hus precluding its use as aP ET tracer.H owever,g iven the potential utility of an AT 2 R-selective imaging agent in individualized management of prostate cancer therapy,t hese resultsp rovide an entry point into the development of future tracers to meet this need.
Experimental Section Chemistry
General
All reagents were purchased at the highest commercial quality and used without further purification. Solvents used for extraction and silica gel chromatography (EtOAc, hexanes, n-pentane, dichloromethane and methanol) were used without purification or desiccation. Yields are for isolated and spectroscopically pure material, unless otherwise stated. Reaction progress was monitored by using thin-layer chromatography (0.25 mm E. Merck silica plates, 60F-254), visualized by fluorescence quenching with UV light at 254 nm or by iodine staining. Silica gel chromatography was carried out by using E. Merck silica gel (60 pore size, particle size 40-63 nm). 1 6 ]DMSO at 39.43 ppm). LC-MS was performed on an instrument equipped with aC P-Sil 8C Bc apillary column (50 3.0 mm, particle size 2.6 mm, pore size 100 ), operating at an ionization potential of 70 eV,u sing a2 min 5-100 %C H 3 CN/H 2 Og radient (0.05 % HCOOH in both CH 3 CN &H 2 O). Accurate mass values were determined by using an electrospray ionization source with a7 -T hybrid ion trap and aT OF detector or through chemical ionization by using ammonia as carrier gas. Sulfonyl azides 1a-1g, [29] precursors 1h-1l, [11] and the non-labeled standards for compounds 2a-2h and 3a-3d [28] were synthesized following the literature procedures and spectral data were in agreement with published values. 
3-[4-[(1 H-Imidazol-1-yl)methyl]phenyl]-5-isobutylthiophene-2-sulfonylazide (1 n)
To as tirred mixture of 1m (55.1 mg, 0.14 mmol) and K 2 CO 3 (86.1 mg, 0.62 mmol) in 1:1 iPrOH/H 2 O( 10 mL) was added imidazole-1-sulfonyl azide hydrogen sulfate (56.8 mg, 0.21 mmol). The reaction mixture was stirred for 16 ha nd then quenched by the addition of 10 mL NaHCO 3 .E tOAc (20 mL) was added and the resulting aqueous phase was extracted with 20 mL EtOAc. The combined organics were washed with brine, dried over Na 2 SO 4 ,a nd concentrated in vacuo. The crude yellow liquid obtained directly after workup was of sufficient purity (ca. 2% starting material, as confirmed by 1 HNMR) to be used directly in Rh I -mediated carbonylation chemistry.P urification by using silica gel chromatography (0-10 %M eOH in CHCl 3 )s ignificantly reduced the isolated yield (colorless liquid, 11 mg, 20 %), possibly owing to stability issues with the sulfonyl azide moiety.T he purified compound was stable for > 1month at À21 8C. 11 C]CO from the CO trap, the transfer gas was changed from helium to xenon (! 99.995 %, 1.5 mL min À1 )a nd the transfer needle was placed into the solvent in as ealed reaction vial (Grace 11 mm silicon/PTFE septum, disposable). Analytical radio-HPLC was carried out by using aV WR LaChrom ELITE system (l-2130, l-2200, l-2400) equipped with aM erck Chromolith Performance RP-18e column (4.6 100 mm). Method:5 -95 %M eCN in H 2 O( 0.05 %T FA), 10 min, 4mLmin
À1
.T he UV signal was monitored at 254 nm and radioactivity was monitored by using aB ioscan Flow-Count PMT radioactivity detector.T he 11 C-labeled carbamates were isolated through semi-preparative HPLC (VWR LaPrep HPLC system P110, P311, equipped with aR eprosil Basic C 18 -HL column, 10 250 mm). Method:5 -95 %M eCN in (NH 4 ) 2 CO 3 (pH 8.9), 8mLmin
.U Vp urity was monitored at 254 nm and radioactivity was monitored by using aB ioscan Flow-Count PMT radioactivity detector.A ll products were identified by co-elution with the corresponding isotopically unmodified compound (prepared following the literature procedure [28] )a nd were > 95 %r adiochemically pure, as confirmed by analytical radio-HPLC (see above). The identity of [ 11 C]C21 was further confirmed by radio-LC-MS (Waters Quattro Premier Genesis C 18 column, 4m particle size, 150 mm 4.6 mm, MS running in selective ion recording ES + mode) and radio-TLC carried out on batches of [ 11 C]C21 prepared for imaging. For radio-TLC, ac o-spot of isotopically unmodified C21 was run with the reaction mixture and its retention was visualized by fluorescence quenching (UV light, 254 nm). This value (in mm) was identical to that of the labeled compound.
General Procedure for the Preparation of Stock Solutions of Catalyst, Ligand, and Alcohol
Three oven-dried flat-bottomed vials (1 mL) were charged with catalyst (2 mmol), ligand (14 mmol), or alcohol (48 mmol), respectively, capped, and flushed with argon gas for 1min. THF (1 mL, freshly distilled over sodium metal, benzophenone indicator) was added by using aH amilton syringe, and argon gas was bubbled through the resulting solution for 30 s. The vials were then vortexed for 5min, after which all stock solutions were homogeneous. Prepared stock solutions of the catalyst could be used for up to 12 h, after which their color gradually changed from light yellow to yellowbrown. Although all reactant vials were sealed and kept filled with argon, atmospheric poisoning by water or oxygen cannot be ruled out (see above for stability screen).
GeneralM ethod for the Preparation of 11 C-Sulfonyl Carbamates 2a-2 ha nd 3a-3 d
An oven-dried conical vial (1 mL, PTFE/silicate crimp cap) was charged with azide (12 mmol), capped, and flushed with argon gas for 30 s. Catalyst and ligand (0.12 and 0.72 mmol, respectively) in THF were added by using aHamilton syringe and the reaction mixture was diluted to at otal volume of 300 mLw ith THF.A lcohol (24 mmol in 50 mLTHF) was added just prior to [ 11 C]CO introduction (typically 10-15 min after catalyst and ligand) to avoid potential side reactions. [ 11 C]CO was introduced into the reaction mixture under as tream of xenon gas (see above) until measured activity peaked. Thereafter,t he reaction vial was placed in ah eating block for 5min, after which activity (A 0 )w as measured in aw ell-counter. In at est reaction (n = 3), the activity in the vial was checked directly after CO introduction and then after heating to see whether any leakage had occurred. We were pleased to observe that all activity remained in the vial. The reaction vial was then equipped with av ent needle and flushed with as tream of nitrogen gas (10 mL min À1 )for 30-60 s, and the remaining activity was measured (see the Supporting Information for ad iscussion on the calculation of the radiochemical yield). An aliquot (typically 1-5 mL) was taken for crude HPLC analysis and comparison with an analytical standard. [28] In parallel, the reaction mixture was diluted with 100 mL 1:1M eCN/H 2 Oa nd purified by semi-preparative HPLC to give 2.2 GBq of sulfonyl carbamate 2a 52 min post EOB (decay-corrected isolated RCY 55 %), starting from 18 GBq [ 11 C]CO. To ensure that the recovery of activity was high and comparable throughout all experiments, HPLC columns, injection ports, and reaction vials were checked for residual activity after all preparative and analytical HPLC runs.
Butyl tosyl-[1- Thiophen-2-ylmethyl tosyl- [1- 11 C]carbamate (2 f) Butyl(benzylsulfonyl)-[1- 2 ,a nd PPh 3 in anhydrous THF was heated to 100 8Cf or 5min. Purification of this mixture with semi-preparative reversed-phase HPLC gave the title compound. After reformulation in phosphate-buffered saline (pH 7.4), the radiochemical purity was > 95 %w ith no detectable amounts of reagents and starting materials present. The product was radiochemically stable after 60 min at ambient temperature in phosphate buffer.
Biological Evaluation
AnimalExperiments
The animals used in this study were handled in accordance with the guidelines set up by the Swedish Animal Welfare Agency and were approved by the local animal ethics committee at Uppsala (permit number:C 11/15). For the biodistribution experiments, healthy female Sprague Dawley rats weighing 300 AE 80 g( mean AE SD) were used. The animals were housed in av entilated and thermo-regulated environment with a1 2h light/dark cycle and were allowed free access to food and water.
Cell Lines
Cells were purchased from the American Type Tissue Culture Collection (ATCC via LGC Promochem, Borås, Sweden). The cells were cultured in RPMI media supplemented with 10 %f etal bovine serum (FBS) and 1% penicillin/streptomycin (PEST) and grown in an incubator at 37 8Ca nd 5% CO 2 .T rypsin-EDTA( 0.25 %t rypsin, 0.02 %E DTAi nb uffer,B iochrom AG, Berlin Germany) was used to detach the cells. As olution of [ 11 C]C21 (50 nm)w as added to plated cells. For blocking, 2 mm of non-labeled C21 was added 45 min before addition of the radiolabeled substance to saturate the receptors. The cells were incubated for 30 min at 4 8Ct op revent internalization. Thereafter,t he media was collected, the cells were detached by using trypsin-EDTAs olution (0.25 %t rypsin, 0.02 %E DTAi nb uffer,B iochrom AG, Berlin, Germany), re-suspended, and the radioactivity in the cells and media was measured to enable calculation of the fraction of cell-bound radioactivity.E xperiments were performed in triplicate. Data were assessed by using an unpaired, two-sided t-test with GraphPad Prism (version 4.00 for Windows GraphPad Software) to determine significant differences (p < 0.05).
Biodistribution
The tissue distribution and kinetics of [ 11 C]C21 were studied by using healthy female Sprague-Dawley rats. Unsedated rats were injected with formulated (phosphate buffer pH 7.4) [ 11 C]C21 (11-13 MBq) through al ateral tail vein as ab olus. The rats were euthanized at defined time points by CO 2 -O 2 inhalation. Selected time points were 10 (n = 2), 20, and 40 min post-injection (n = 1f or 20 and 40 min). In total, blood and 13 organs were collected; blood, heart, lungs, liver,p ancreas, spleen, adrenals, kidneys, intestines (with and without contents), ovaries, muscle, and brain. The radioactivity and weight of all of the collected organs were measured and the injection site was checked for residual activity.T he organ uptake of [ 11 C]C21 was expressed as SUVs, according to Equation (1) . RA (Bq/g) is the concentration of radioactivity in the organ, InjRA (Bq) is the amount of radioactivity injected, and TBW (g) is the total body weight of the animal. All radioactivity measurements were corrected for decay.
SUV ¼
RA Bq=g ðÞ InjRA Bq ðÞ =TBW g ðÞ ð1Þ
Small-Animal PET
Twom ale Sprague-Dawley rats were anesthetized with isoflurane (2-3 %) in a5 0/50 %m ixture of oxygen and air and placed on the temperature-controlled bed of as mall-animal PET/CT scanner (Triumph trimodality,G EH ealthcare). They were positioned with the abdomen in the field of view.T hereafter,[ PET scan was conducted for 40 min, followed by aC Ts can. PET data were reconstructed by using maximum likelihood estimation maximization (10 iterations). Volumes of interest (VOIs) were drawn manually in the averaged images, for the liver,a nd in early frames, for the kidney and aorta. VOIs were then transferred to all frames to generate time-activity curves.
